All In Biotech

Drug Trial Radar · NCT07615426

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Phase 1b Study to Investigate the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Jun 21, 2027

Study completion Dec 3, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • AticaprantDrug

    Participants will receive aticaprant during the double blind (DB) treatment phase.

  • PlaceboDrug

    Participants will receive placebo during the DB treatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Screen Pass RateTime frame: Up to 28 days
  2. Exploratory Assessment-Specific Completion RateTime frame: Up to 126 days
  3. Total Assessment Completion RateTime frame: Up to 126 days
  4. Study Completion RateTime frame: Up to 126 days
  5. Adverse Events (AEs) Including AEs of Special Interest (AESI)Time frame: Up to 126 days
  6. Number of Participants with Abnormalities in Vital SignsTime frame: Up to 126 days
  7. Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)Time frame: Up to and including 85 days
  8. Number of Participants with Abnormalities in Laboratory ParametersTime frame: Up to and including 85 days
  9. Number of Participants Reporting Changes in Body WeightTime frame: Up to and including 85 days
  10. Number of Participants Reporting Changes in Body Mass Index (BMI)Time frame: Up to and including 85 days
  11. Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over TimeTime frame: Up to 126 days
  12. Extrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total ScoreTime frame: Up to and including 85 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • CNS Network

    Garden Grove, California · Recruiting

  • Synexus Clinical Research US Inc

    Atlanta, Georgia · Recruiting

  • Uptown Research Institute

    Chicago, Illinois · Recruiting

  • Western Michigan University

    Kalamazoo, Michigan · Completed

  • Neurobehavioral Research Inc

    Cedarhurst, New York · Recruiting

  • Evolution Research Group

    Staten Island, New York · Recruiting

  • Community Clinical Research, Inc.

    Austin, Texas · Recruiting

  • Pillar Clinical Research, LLC

    Richardson, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.